Fabry Disease Clinical Trials

A listing of Fabry Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
China Post-marketing Surveillance (PMS) Study of Fabrazyme®

Fabry Disease.

neuropathic pain
cornea verticillata
agalsidase beta
replacement therapy
cardiomyopathy
  • 0 views
  • 22 Jan, 2022
  • 2 locations
Study of the Effects of Fabrazyme Treatment on Lactation and Infants

The study will last for up to 2 years (24 months). Full participation for both mother and infant is 24 months, full participation of mother and development of infant is 24 months, while full participation of mother and no infant participation is 6 months

agalsidase beta
fabrazyme
  • 75 views
  • 23 Jan, 2022
  • 2 locations
Study of the Effects of Fabrazyme Treatment on Lactation and Infants

The study will last for up to 2 years (24 months). Full participation for both mother and infant is 24 months, full participation of mother and development of infant is 24 months, while full participation of mother and no infant participation is 6 months

agalsidase beta
fabrazyme
  • 0 views
  • 22 Jan, 2022
  • 2 locations
Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease.

assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC ) in the ATTRh form and correlate with other

monoclonal gammopathy
brain natriuretic peptide
elastography
MRI
immunohistochemistry
  • 0 views
  • 27 May, 2021
  • 1 location
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment

replacement therapy
agalsidase beta
alpha-galactosidase
deficit
deficiency
  • 456 views
  • 23 Jan, 2022
  • 250 locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment

replacement therapy
agalsidase beta
alpha-galactosidase
deficit
deficiency
  • 0 views
  • 23 Jan, 2022
  • 250 locations
Canadian Fabry Disease Initiative (CFDI) National Registry (CFDI-NR)

CFDI NATIONAL REGISTRY Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes

genetic disorder
neuropathic pain
alpha-galactosidase
deficit
deficiency
  • 149 views
  • 23 Jan, 2022
  • 5 locations
Screening for Fabry Disease in Renal Transplantation

Single centre, prospective pilot study examining the relevance to screen for Fabry disease in a cohort of patients who have undergone renal transplantation for nephropathy of indeterminate cause

  • 0 views
  • 23 Jan, 2021
  • 1 location
Evaluation of HEArt invoLvement in Patients With FABRY Disease

This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.

arrhythmia
heart failure
sudden cardiac death
  • 20 views
  • 24 Jan, 2021
  • 3 locations
Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease Patients

Fabry disease is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme -Gal A resulting from mutations affecting the GLA gene. It is characterized by

deficit
gla gene
globotriaosylceramide
lyso-gb3
renal function
  • 0 views
  • 29 Sep, 2021
  • 1 location